.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Testosterone - Generic Drug Details

« Back to Dashboard
Testosterone is the generic ingredient in eighteen branded drugs marketed by Eli Lilly And Co, Abbvie, Auxilium Pharms Inc, Watson Labs, Actavis Labs Ut Inc, Par Pharm, Auxilium Pharms, Alza, Endo Pharms, Ani Pharms Inc, Perrigo Israel, Aytu Bioscience Inc, Allergan Sales Llc, Upsher-smith Labs, Sandoz, Sun Pharm Inds Ltd, Paddock Llc, Pharmacia And Upjohn, Hikma Farmaceutica, Mylan Institutional, Eurohlth Intl Sarl, Bel Mar, Lilly, Elkins Sinn, and Endo Pharms Inc, and is included in forty-seven NDAs. There are forty-five patents protecting this compound and six Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

This ingredient has three hundred and seventy-five patent family members in forty-six countries.

There are sixty-one drug master file entries for testosterone. Nineteen suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for Generic Name: testosterone

Tradenames:18
Patents:45
Applicants:25
NDAs:47
Drug Master File Entries: see list61
Suppliers / Packaging: see list19
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)
Formulation / Manufacturing:see details
Drug Prices:see low prices

Pharmacology for Ingredient: testosterone

Ingredient-typeAndrostanes
Drug ClassAndrogen
Mechanism of ActionAndrogen Receptor Agonists

Tentative approvals for TESTOSTERONE

Applicant Application No. Form Dosage
<disabled><disabled>SOLUTION;TOPICAL30MG/1.5ML
<disabled><disabled>SOLUTION;TOPICAL30MG/1.5ML
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
ANDROGEL
testosterone
GEL, METERED;TRANSDERMAL022309-001Apr 29, 2011RXYes6,503,894*PED► subscribeY► subscribe
Watson Labs
TESTOSTERONE CYPIONATE
testosterone cypionate
INJECTABLE;INJECTION086030-001Approved Prior to Jan 1, 1982RXNo► subscribe► subscribe
Endo Pharms Inc
AVEED
testosterone undecanoate
INJECTABLE;INTRAMUSCULAR022219-001Mar 5, 2014RXYes► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: testosterone

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Auxilium Pharms
TESTIM
testosterone
GEL;TRANSDERMAL021454-001Oct 31, 20025,023,252► subscribe
Allergan Sales Llc
ANDRODERM
testosterone
FILM, EXTENDED RELEASE;TRANSDERMAL020489-001Sep 29, 19954,863,970► subscribe
Allergan Sales Llc
ANDRODERM
testosterone
FILM, EXTENDED RELEASE;TRANSDERMAL020489-002May 2, 19974,849,224► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: testosterone

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,929,801 Transdermal delivery of antiparkinson agents► subscribe
6,624,200 Bioadhesive progressive hydration tablets► subscribe
8,765,177Bioadhesive progressive hydration tablets► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: testosterone

Country Document Number Estimated Expiration
Austria319426► subscribe
South Africa200904568► subscribe
Hong Kong1061804► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TESTOSTERONE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00523Netherlands► subscribePRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006
2012 00012Denmark► subscribe
00521Netherlands► subscribePRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc